{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:00:16Z","timestamp":1791262816393,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,11,23]],"date-time":"2009-11-23T00:00:00Z","timestamp":1258934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p>(<jats:italic>Cancer Sci<\/jats:italic> 2010; 101: 793\u2013799)<\/jats:p><jats:p>Cetuximab is a monoclonal antibody targeting epidermal growth factor receptor (EGFR). The present study investigated the association between germline genetic polymorphisms and the treatment outcome of cetuximab plus modified leucovovin, fluorouracil, and oxaliplatin (FOLFOX)6 chemotherapy in advanced gastric cancer (AGC). DNA from peripheral blood mononuclear cells of 38 patients enrolled in a phase II study of cetuximab plus modified FOLFOX6 were analyzed for 16 polymorphisms in eight genes (EGFR, epidermal growth factor, transforming growth factor\u2010\u03b1 (TGFA), thymidylate synthase, excision repair cross\u2010complementation group 1, <jats:italic>Xeroderma pigmentosum<\/jats:italic> group D, and fragment c gamma receptors (FCGR)2A and 3A). The EGFR intron 1 CA repeat polymorphism was associated with survival. Twenty\u2010one patients had low repeats (sum of both alleles \u226437), and 17 patients had high repeats (sum \u226538). Patients with low CA repeats had longer progression\u2010free survival (adjusted hazard ratio [HR] 0.42 [95% confidence interval [CI] 0.19\u20130.96], <jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.040) and overall survival (adjusted HR 0.40 [95% CI 0.16\u20130.99], <jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.048) compared with patients with high CA repeats. In addition, the tumor EGFR expression was higher in patients with a lower number of CA repeats. The association between the CA repeat status and survival was not found in a separate cohort of AGC patients (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>68) treated only with modified FOLFOX6. These results suggest that the EGFR intron 1 CA repeat polymorphism could be a useful, predictive biomarker of cetuximab efficacy in AGC and merits further investigation in randomized studies.<\/jats:p>","DOI":"10.1111\/j.1349-7006.2009.01447.x","type":"journal-article","created":{"date-parts":[[2009,11,23]],"date-time":"2009-11-23T12:14:18Z","timestamp":1258978458000},"page":"793-799","source":"Crossref","is-referenced-by-count":20,"title":["Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6"],"prefix":"10.1111","volume":"101","author":[{"given":"Sae\u2010Won","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do\u2010Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock\u2010Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Ryun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun\u2010Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Suk","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam\u2010Su","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Sil","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung\u2010Jue","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae\u2010You","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.2308"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2007.39.4.139"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-008-2177-6"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.18_suppl.lba4509"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.504"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071834"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805019"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804385"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.9170"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl459"},{"key":"e_1_2_6_12_2","article-title":"Cetuximab plus weekly oxaliplatin\/5FU\/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group","volume":"25","author":"Lordick F","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"e_1_2_6_13_2","unstructured":"Erbitux in combination with Xeloda and cisplatin in advanced esophago\u2010gastric cancer (EXPAND) (ClinicalTrials.gov number NCT00678535)."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206749"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604861"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-148"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328011abc0"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8397"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0786"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn541"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70102-9"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm492"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5437"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8021"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4602"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"e15503","DOI":"10.1200\/jco.2009.27.15_suppl.e15503","article-title":"KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients","volume":"27","author":"Stella G","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040125"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9409-5"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1036"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500444"},{"key":"e_1_2_6_32_2","first-page":"1009","article-title":"Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism","volume":"9","author":"Liu W","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1542"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60569-9"},{"key":"e_1_2_6_35_2","first-page":"854","article-title":"Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression","volume":"60","author":"Buerger H","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi189"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0247"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1323"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2009.01447.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2009.01447.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:12:17Z","timestamp":1697429537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2009.01447.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,17]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1349-7006.2009.01447.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01447.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,17]]}}}